SUBSCRIBE
SUBSCRIBE

AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
1 North Waukegan Road
North Chicago, IL 60064
Tel: 1-800-255-5162
Visit website
Email Us
Stock Symbol: ABBV
Stock Exchange: NYSE
  • Featured Employer
NEWS
Pictured: Aerial view of the San Francisco skyline
Now Hiring
8 Companies Hiring in San Francisco
Looking for a biopharma job in San Francisco or South San Francisco? Check out the BioSpace list of eight companies hiring life sciences professionals like you.
August 28, 2025
 · 
1 min read
 · 
Chantal Dresner
Podcast
Lilly’s Obesity Pill Heads to the FDA, AbbVie Bets on Psychedelics, HHS Unveils More Change
Eli Lilly drops a second Phase III readout for orforglipron; AbbVie committed to the psychedelic therapeutics space with the $1.2 billion acquisition of Gilgamesh’s depression asset; the CDC taps vaccine skeptic Retsef Levi to lead its COVID-19 immunization working group; and the FDA prioritizes overall survival in cancer drug development.
August 27, 2025
 · 
1 min read
 · 
Jef Akst
Brain doodle illustration, sketched colored concept about fresh ideas in human mind
Acquisitions
Unswayed by Cerevel Failure, AbbVie Buys Gilgamesh’s Depression Drug for $1.2B
The deal extends AbbVie’s commitment to the psychedelics space and depression, after emraclidine’s high-profile flop in schizophrenia last November.
August 25, 2025
 · 
3 min read
 · 
Annalee Armstrong
Photo of Boston, Massachusetts, at the Boston Harbor and Financial District with a mix of contemporary and historic architecture.
Job Trends
9 Companies Hiring Now in Massachusetts
Looking for a biopharma job in Massachusetts? Check out the BioSpace list of nine companies hiring life sciences professionals like you.
August 21, 2025
 · 
1 min read
 · 
Chantal Dresner
Houston, Texas downtown city park and skyline
Job Trends
6 Companies Hiring in Texas
Looking for a biopharma job in Texas? Check out the BioSpace list of six companies hiring life sciences professionals like you.
August 14, 2025
 · 
1 min read
 · 
Angela Gabriel
Pictured: Office building science collage
Career Advice
The Top 12 Companies Hiring in Biopharma Now
Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.
August 7, 2025
 · 
1 min read
 · 
Chantal Dresner
Close-up image of human hand holding wrench. Construction
Earnings
Biopharma CEOs Can’t Dodge Policy Questions as Trump Lobs Wrench into Earnings Season
From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.
August 6, 2025
 · 
6 min read
 · 
Annalee Armstrong
AbbVie's office in South San Francisco, California
Earnings
AbbVie Pats Own Back as Skyrizi and Rinvoq Rake in Billions
Move over Humira, Skyrizi and Rinvoq are expected to beat the former megablockbuster’s peak sales by the end of this year.
July 31, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
woman hand is removing hair from blue brush. A Hair care.
Immunology and inflammation
AbbVie Carves Out Niche for Rinvoq With ‘Impressive’ Alopecia Areata Data
Rinvoq’s efficacy in alopecia areata is “impressive,” according to Guggenheim analysts, who said the drug could have a competitive edge over other JAK inhibitors in the space.
July 31, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
JOBS
View All Jobs at AbbVie
IN THE PRESS
Press Releases
RINVOQ® (upadacitinib) Receives Health Canada Notice of Compliance (NOC) for Giant Cell Arteritis in adults
August 28, 2025
 · 
6 min read
Press Releases
AbbVie to Acquire Gilgamesh Pharmaceuticals’ Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline
August 26, 2025
 · 
6 min read
Press Releases
AbbVie Announces Positive Topline Results from Second Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata
August 21, 2025
 · 
18 min read
Press Releases
SkinMedica® Unveils Its Newest Hydration Hero
August 20, 2025
 · 
13 min read
Press Releases
AbbVie Completes Acquisition of Capstan Therapeutics
August 20, 2025
 · 
3 min read
Press Releases
AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S.
August 13, 2025
 · 
3 min read
Press Releases
AbbVie Announces Positive Topline Results from Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata
July 31, 2025
 · 
18 min read
Press Releases
AbbVie Submits for U.S. FDA Approval of Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
July 30, 2025
 · 
12 min read
Press Releases
AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
July 11, 2025
 · 
7 min read
Press Releases
AbbVie to Host Second-Quarter 2025 Earnings Conference Call
July 1, 2025
 · 
1 min read
Load More